Legend Biotech Corporation
Legend Biotech Corporation (LEGN) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
legn · stock forecast · 19 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Buy
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$75.00
Consensus
$59.78
+83.3% upside
Low
$24.00
Median: $65 · Last Close: $32.62
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$59.78
83.3% upside
High Target
$75
129.9%
Low Target
$24
-26.4%
Current Price
$32.62
as of today
Based on analyst price targets, the LEGN stock price prediction for the next 12 months ranges from $24 to $75. The consensus LEGN price forecast of $59.78 implies 83.3% upside from the current price of $32.62.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $32.62 | ↑ 0.00% |
1-day model range: $32.39–$32.85. Peak: $32.85 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · LEGN · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-06-03 | UBS | Maintains | Buy→Buy |
| 2026-05-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-05-13 | RBC Capital | Maintains | Outperform→Outperform |
| 2026-05-13 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-05-13 | TD Cowen | Maintains | Hold→Hold |
| 2026-04-21 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-04-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-03-11 | Morgan Stanley | Maintains | Overweight→Overweight |
| 2026-03-11 | RBC Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Legend Biotech Corporation (LEGN) stock. Of the recent 124 rating actions, 2 were upgrades and 2 were downgrades. 19 analysts currently cover LEGN.
Analyst Recommendation Trends
LEGN analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1.4B
↓ 32.3% YoY
Revenue Next Year
$1.8B
↑ 26.2% YoY
EPS This Year
$0.09
EPS Next Year
$0.92
↑ 909.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast LEGN EPS of $0.09 for the current fiscal year, based on estimates from 4 analysts. The LEGN revenue forecast is $1.4B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The LEGN stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus LEGN price target is $59.78 (+83.3% upside), with an analyst consensus of Buy.
The LEGN short-term stock prediction for tomorrow is $32.62 (+0.00%).
Legend Biotech Corporation trades on NASDAQ under the ticker LEGN. The LEGN stock outlook for 2027 is broadly positive, supported by a Buy consensus among 84% of covering analysts.
Frequently asked questions
LEGN forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month LEGN price target is $59.78, with a high forecast of $75.00 and a low of $24.00. The median price target is shown in the chart above when available. This implies +83.3% potential upside from the current price of $32.62.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.